T he incidence of hepatocellular carcinoma (HCC) in the United States has doubled over the past 2 decades, resulting in an estimated 1 billion dollars in direct and indirect health care costs. 1, 2 Because the prognosis of advanced HCC is poor, surveillance for the detection of small tumors in high-risk populations has become common practice. The majority of gastroenterologists use semiannual ultrasound and the serum tumor marker ␣-fetoprotein (AFP) to detect HCC in cirrhotic patients, 3 of whom 2% to 8% develop the tumor annually. 4, 5 Studies suggest that surveillance detects tumors at earlier stages and improves survival. 6, 7 Recent guidelines from the American Association for the Study of Liver Diseases advocate annual or semiannual surveillance with ultrasonography (US) in cirrhosis. 8 Because its sensitivity and specificity are limited, the use of AFP is recommended only when ultrasound is unavailable.
The cost effectiveness of HCC surveillance with US alone in a general population of cirrhotic patients has not been evaluated in the United States. Surveillance with AFP and US, or with computed tomography (CT), has been shown to be cost effective in select populations such as liver transplant candidates and hepatitis C cirrhotic patients. 9 -14 With improvements in treatment options for small tumors and the diagnostic accuracy of radiologic imaging, routine surveillance for HCC in cirrhosis is more likely to provide benefit.
In recent years, local ablative therapies such as radiofrequency ablation have permitted patients with advanced liver disease or comorbidities that preclude resection or transplantation to be treated successfully. 15 Liver transplantation is not only a viable treatment for HCC, but changes to the Model for End-Stage Liver Disease scoring system now give patients with small tumors priority in the transplant process. For patients meeting the Milan criteria, those with a single HCC less than 5 cm or no more than 3 tumors each smaller than 3 cm, longterm survival posttransplant approaches that observed for nonmalignant indications. 16 As survival improves, the consequences of missing small HCC grow.
The range of available screening modalities for HCC also has expanded. Although US is recommended for surveillance, CT is used increasingly frequently for surveillance by clinicians. 3 CT or magnetic resonance imaging (MRI) may be more sensitive in detecting small HCC. 17, 18 The relative performance and costs of these tests in surveillance program has not been evaluated formally.
With the imminent peak in hepatitis C cirrhosis and the increasing incidence of nonalcoholic fatty liver disease, the burden of HCC is expected to grow. In light of potentially more effective, yet expensive, diagnostic tests and treatments, we used the best available data to estimate the benefits, costs, and cost effectiveness of US alone compared with alternative surveillance strategies for HCC in cirrhosis.
Methods

Analytic Overview
We developed a computer-based Markov model (TreeAge Pro software 2005; TreeAge Software, Inc, Williamstown, MA) to simulate surveillance, diagnosis, and treatment of HCC in a cohort of patients with compensated cirrhosis. In comparison with no surveillance, we assessed: (1) annual US, (2) semiannual US, (3) semiannual US with AFP, (4) annual CT, (5) semiannual CT, and (6) annual MRI surveillance. Model outcomes included the number of screening tests needed to diagnose one small HCC, cost per treated HCC, lifetime costs, quality-adjusted life expectancy, and incremental cost-effectiveness ratios (2004 US$ per quality-adjusted life year [QALY] gained). We adopted a health system perspective and followed the recommendations of the Panel on Cost-Effectiveness in Health and Medicine. One-way and 2-way sensitivity analyses were performed to identify individual parameters with the greatest influence on our results.
Model
A cohort of 50-year-old individuals representative of patients with cirrhosis in the United States enter the model and move through a series of health states designed to reflect important stages in the natural history of cirrhosis, tumor progression, and treatment ( Figure 1 ).
Surveillance Algorithms and Treatment
To estimate the effect of surveillance, the model distinguishes between detected and undetected HCC. Depending on the accuracy and timing of surveillance and the tumor growth rate, HCC might be detected early or remain undetected until an advanced stage. Patients with compensated cirrhosis in whom small HCC was detected (defined as tumors meeting Milan criteria) were eligible for liver transplantation, resection, or local ablative therapies; whereas decompensated cirrhotic patients were eligible for transplant or local ablation. Patients with advanced tumors received only palliative care.
A number of assumptions were made in the base case including the following: (1) a positive US was evaluated with a dynamic imaging study, either triple-phase CT or MRI, as recommended by the American Association for the Study of Liver Diseases guidelines; (2) serum AFP level was considered positive if greater than 20 ng/mL cut-off level, and was evaluated with dynamic imaging even when the corresponding US was negative; (3) suspicious lesions found on imaging underwent a biopsy; (4) no additional imaging was performed before a biopsy in the CT or MRI strategies; and (5) patients with falsepositive test results returned to their previous surveillance test and schedule once a biopsy confirmed their true disease status. Natural history of cirrhosis. Based on large epidemiologic studies, the average life expectancy of compensated cirrhosis is between 10 and 13 years. 19 Between 5% and 7% of compensated cirrhotic patients progress to decompensated disease each year, developing ascites, variceal bleeding, or encephalopathy. The median life expectancy of decompensated disease is 2 years. 19 -21 Because 20% of the annual excess mortality from cirrhosis is attributable to HCC, we adjusted mortality rates accordingly to avoid double-counting HCC deaths. 19 -21 With this adjustment, predicted life expectancy for compensated cirrhosis in the model approximated that reported in the literature.
Data
Incidence and progression of hepatocellular carcinoma. The annual incidence of HCC is approximately 5%, with a range of 2% to 8% in cohort studies of cirrhotic patients undergoing surveillance. 4 -6,22,23 The median survival for patients with small or advanced HCC is 2 years or 6 months, respectively. 24 -26 Tumor growth was assumed to be linear, with a doubling time between 117 and 195 days. 25, 27, 28 Based on this doubling time, approximately 40% of tumors progress from a limited to an advanced stage each year.
Surveillance test characteristics. The sensitivity of US for HCC surveillance ranges from 40% to 81% and its specificity ranges from 80% to 100%. 29 -33 The sensitivity of triple-phase CT is higher (85%-90%), but its specificity is similar (80%-96%). 17, 29, 30, [33] [34] [35] [36] Serum AFP is far less sensitive (40%-65%) and specific (63%-94%) at the 20 ng/mL cut-off level. 37, 38 The sensitivity and specificity of MRI approach 90%. 33, 39, 40 Because Figure 1 . Simplified schematic of Markov health states. In each cycle, individuals may remain in the same health state, transition to the following state, or die from liver disease or unrelated causes. For example, transition 1 reflects cancer incidence; transition 2 is determined by the sensitivity of the surveillance modality; and transition 3 is the proportion of treatmenteligible tumors. Best available data were used to determine transitions. The grey boxes represent the possible benefit of surveillance: detection and treatment of small HCC.
test characteristics vary widely in the literature, preference was given to studies using a screening framework and pathologic gold standard.
Risks and prognosis of hepatocellular carcinoma treatment. After successful transplantation for small HCC, 5-year survival approaches 70%. 16, 41, 42 Five-year survival after resection is less than 50% because of tumor recurrence. 41, [43] [44] [45] Five-year survival with radiofrequency ablation ranges from 31% to 46%, depending on the underlying liver disease. 15, 46 Radiofrequency ablation was evaluated as the sole local therapy because its efficacy is similar to chemoembolization and ethanol injection, 47 and it is widely available in the United States. The perioperative mortality of transplant, resection, and radiofrequency ablation is 4.3%, 42 3.9%, 41 and 0.3%, 48 respectively. Because systemic chemotherapy and other treatments for advanced disease have not improved survival significantly, 49, 50 advanced cancer was not treated in the model.
We consulted 4 expert hepatologists to estimate the proportion of small HCC eligible for treatment with curative intent because published data on this parameter are sparse. By conservative estimates, approximately 70% of compensated and 30% of decompensated cirrhotic patients with small HCC are Annual incidence of HCC 4-6,23 5% 2%-6% Annual transition from small to large HCC 25, 28 40% 20%-70% Annual mortality from large untreated HCC 49, 50 75% 35%-95% Liver transplant prognosis 16, 41, 42 Perioperative mortality 4.3% 2.3%-6.3% 5-year survival 70% 65%-80% Hepatic resection prognosis 41, [43] [44] [45] Perioperative mortality 3.9% 3.7%-4.5% 5-year survival 44% 38%-51% Local ablative therapy (radiofrequency ablation) prognosis 15, 46 Perioperative mortality 0.3% 0%- treatment-eligible. Based on a Medicare study of patients with HCC, we assumed that the proportion of treatment-eligible compensated cirrhotic patients undergoing resection, local ablation, and transplant was 40%, 40%, and 20%, respectively. 51 We assumed that 40% of treatment-eligible decompensated cirrhotic patients were transplant-eligible. We varied these estimates widely in sensitivity analyses.
Costs and quality of life. Direct medical costs were derived from 2004 Medicare Current Procedural Terminology reimbursement, the 2003 Nationwide Inpatient Sample, and published literature. 10, 52, 53 The annual costs of cirrhosis management included office visits, blood work, and occasional hospitalizations for decompensation, but not transplantation. Literature-based estimates were used for the quality-of-life weights. [52] [53] [54] 
Results
Life Expectancy
For compensated cirrhotic patients ages 50 and older, the average per-person quality-adjusted life expectancy (QALE) is 7.3 years in the absence of surveillance. The undiscounted gain in QALE is 6.8 months with annual US. Increasing the US frequency to twice yearly provides an additional 1.8 months of QALE. Incremental gains from the other strategies are smaller; for example, adding serum AFP improves the effectiveness of semiannual US by only 0.6 months ( Table 2) . Although semiannual US increases average QALE by 8.6 months, it extends it nearly 3.5 years in patients with diagnosed and treated small HCC.
Lifetime Costs and Cost-Effectiveness Analysis
The average discounted lifetime cost in the absence of surveillance for 50 year-old cirrhotic patients is $26,200. Discounted lifetime per-person cost increases by $8000 with annual US and by $19,700 with MRI ( Table 2 ). The incremental cost-effectiveness ratio (ICER) for annual US is $21,200 per QALY gained. In comparison, semiannual US provides nearly 2 additional months of QALE for $30,700 per QALY. Adding serum AFP yields smaller gains in QALE and has an ICER of $73,500/QALY. Semiannual CT, the most effective strategy, has an ICER exceeding $300,000/QALY. Annual MRI is more costly and less effective than both of these strategies.
Clinical Impact and Resource Use of Semiannual Surveillance
The clinical impact and resource use of semiannual US surveillance in a model cohort of 10,000 cirrhotic patients age 50 and older are reported in Table 3 . Over a 30-year period, more than 180,000 ultrasounds are performed with an estimated 3000 small tumors detected. Therefore, approximately 60 surveillance US are required to detect one small HCC. The average costs per detected and treated small HCC were $117,200 and $179,900, respectively.
Sensitivity Analysis
Sensitivity analyses were performed on all model parameters to identify the most influential variables. The cost effectiveness of surveillance is most sensitive to assumptions about population age, the mortality of HCC, and its rate of progression. The cost of surveillance exceeds $50,000/QALY if the annual incidence of HCC is less than 0.8%, fewer than 14% of tumors progress from limited to advanced each year, or patient age exceeds 83 years.
The effect of varying selected parameters on the incremental cost effectiveness of semiannual US surveillance is shown in Figure 2 . If the annual incidence of HCC decreases to less than 2.2%, annual US is preferred to semiannual US based on the $50,000/QALY threshold. When US sensitivity is lower than 65% or the specificity of AFP exceeds 95%, combined AFP/US surveillance is preferred. Annual CT becomes the preferred strategy when US specificity is less than 60%. The ICERs of semiannual CT and annual MRI consistently exceed $100,000/ QALY.
In 2-way sensitivity analysis, we simultaneously varied the test characteristics of US, CT, and MRI. When US sensitivity is poor (0.5), combined AFP/US surveillance is preferred for all tested sensitivities of CT and MRI. Otherwise, semiannual US surveillance is cost effective in all conditions tested.
Discussion
Our analysis shows that surveillance for HCC in patients with cirrhosis provides substantial life-expectancy gains. a Annual CT and MRI are dominated by semiannual ultrasound, which is both a more effective and less costly strategy. Semiannual US surveillance extends QALE by 8.6 months compared with no surveillance, a benefit that compares favorably with screening programs for colon or breast cancer. 55, 56 The QALE gain for cirrhotic patients with detected and treated small HCC exceeds 3 years. The utility of surveillance in cirrhosis is unsurprising because the incidence of HCC is high; the tumor often is asymptomatic and unlikely to be detected without surveillance; and treatments are effective for early HCC, whereas the prognosis for advanced disease is poor. With continued improvement in the life expectancy of cirrhosis and the treatments for HCC, the benefit of surveillance is likely to increase. There is no consensus on a cost-effectiveness threshold below which an intervention would be considered unequivocally cost effective, but a value of $50,000/QALY often is cited as a benchmark for the United States. At this threshold, semiannual US ($30,700/QALY) is attractive. Although one could argue that society has been willing to pay up to $100,000/QALY for certain health interventions, in which case AFP/US confers reasonable value for the money ($73,500/QALY), CT and MRI surveillance would not be considered cost effective under widely varying assumptions.
We found that only when US sensitivity and specificity decrease to less than 65% and 60%, respectively, do the AFP/US or annual CT strategies become preferred at the $50,000/QALY benchmark. Based on the results of published studies, test characteristics are unlikely to fall into this range. However, in circumstances in which US sensitivity or specificity might be poor, such as in patients with ascites, individual decision making should prevail. As single tests, CT and MRI are more sensitive than US for detecting small HCC; however, when performed annually these tests are less effective than semiannual US. The rapid doubling time of HCC favors a semiannual surveillance schedule. Semiannual CT provides a smaller incremental benefit at a higher cost. US surveillance also improves with improving characteristics of CT and MRI because the latter are used as confirmatory tests. Our analysis did not consider the risks of radiation or contrast with CT, factors that may further favor US in practice. We also did not consider strategies combining AFP with CT or MRI. Combining frequent AFP measurements with annual CT or MRI is unlikely to be more effective given the limited sensitivity of AFP compared with advanced imaging.
The addition of AFP to US increases detection of HCC somewhat, but is more costly because falsely positive AFP increases prompt additional imaging studies. This cost increases further if AFP levels lower than the 20 ng/mL cut-off trigger further testing. Despite using favorable test characteristics for AFP, the cost of the combined strategy exceeds $50,000/QALY. We did not include newer serum tumor markers such as AFP-L3 because they are not yet validated for use in screening. If their test characteristics prove to be significantly better than AFP, a combined strategy may become favorable.
Our results are reasonably consistent with prior cost-effectiveness analyses of HCC surveillance, although no study has evaluated surveillance with US alone in a general population of cirrhotic patients in the United States. Sarasin et al 10 evaluated semiannual AFP/US surveillance in compensated cirrhotic patients. They considered surgical resection as the sole treatment modality. Under a best-case scenario, the average life expectancy gain from surveillance was 9 months. The cost effectiveness ranged from $26,000 to $284,000 per life-year gained. Three studies of surveillance in hepatitis C cirrhosis reported similar cost-effectiveness estimates but did not consider the use of US alone. [11] [12] [13] A recent study in the United Kingdom comparing surveillance with combined AFP/US to strategies using AFP or US alone in alcoholic, hepatitis B virus, and hepatitis C virus cirrhosis found that semiannual AFP/US was most effective but exceeded the typical willingness-to-pay threshold of £30,000/ QALY. 14 In this population, a novel AFP triage strategy, in which increased AFP levels (Ͼ20 ng/mL) triggered a diagnostic US, captured much of the clinical benefit of surveillance at a reasonable cost. We did not consider this strategy because an increased AFP level typically is evaluated with CT or MRI in the United States. However, our results suggest that US alone would be a similarly efficient strategy in the United States.
This analysis had several limitations. Because the performance of imaging tests under specific conditions was not described in published studies, we assumed that test characteristics were independent of patient characteristics and tumor size. The preferred strategy may differ if a test consistently performs poorly in patient subgroups, such as patients with obesity. Similarly, because of methodologic differences in published imaging studies, the sensitivities and specificities of US, CT, and MRI used in this study may refer to tumors of different sizes. Although MRI studies typically incorporate missed subcentimeter lesions into the sensitivity calculations, no lesion this small is detected by US in any study. However, our findings did not differ when each test was assigned perfect test characteristics in sensitivity analyses. Our model was limited by the lack of published data on certain parameters, such as the proportion of small HCCs treated with curative intent, but surveillance remained cost effective even when these parameters were varied widely in sensitivity analyses. The actual costs of surveillance may be underestimated if clinical practice deviates significantly from our assumptions.
The risk of HCC varies among the different etiologies of cirrhosis, although the precise risk for some etiologies is not well defined. Surveillance of cirrhotic populations with a relatively low risk, such as patients with primary biliary cirrhosis, appears justified by our finding that surveillance remains cost effective even when the annual incidence of cancer is 0.8%. However, in low-risk populations, annual US surveillance may be preferable. Because our natural history parameters derive from Western populations with mixed etiologies of cirrhosis and our cost data are US based, cost-effectiveness estimates may differ in specific cirrhotic populations and in other countries.
The results of our study predict that surveillance for early HCC improves clinical outcomes. Our findings support recent American Association for the Study of Liver Diseases guidelines recommending surveillance with US alone. Although the preferred strategy may vary in specific situations, we found that semiannual US is both effective and cost effective for routine surveillance for HCC in cirrhosis.
Additional references used to define the variable ranges for sensitivity analyses are available online as supplemental materials at www.cghjournal.org.
